

Merodis advised Sophia Genetics with its CHF 15m Series C Financing.

December, 15nd 2015, Brussels, Belgium

Merodis, a corporate finance consulting firm, is proud to announce it successfully assisted Sophia Genetics with its CHF 15m Series C financing which was led by Marc Coucke's investment firm Alychlo, alongside the existing shareholders.

The proceeds will be used amongst others to further accelerate an already impressive market roll-out of Sophia Genetics' offering, hence further boosting its projected growth and market dominance within its specific domain in Europe.

Sophia Genetics (www.sophiagenetics.com) is the global leader in Data Driven Medicine (DDM) hosting the world's largest clinical genomics community for molecular diagnosis through its platform, Sophia DDM™, hereby placing Europe ahead of the US in precision medicine. The company currently supports over 110 institutions across 20 countries, and is positioning as the largest global market player for interpreting pseudonymised genomics data and promoting experts' knowledge sharing for genomic variants clinical interpretation.

For more information, please contact:

Dirk Marckx, dma@merodis.com , +32 495 38 17 81

Thierry Hazevoets, tha@merodis.com , +32 495 58 68 98

About Merodis

Part of the euroMerger international network, Merodis provides middle-market companies with a wide range of financial advisory services in support of mergers, acquisitions, divestitures, capital raising and corporate restructuring. For detailed information concerning the range of services offered, recent transactions and credentials, please consult www.merodis.com

If you no longer wish to receive this information, please send an email with subject "Unsubscribe" to info@merodis.com. If you want to be informed on new investment opportunities or get the latest news about Merodis, please click <http://www.merodis.com/contact.php?l2=1>